• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Harnessing Invariant NKT Cells to Improve Influenza Vaccines: A Pig Perspective

tetano

Editor, Senior Moderator
Int J Mol Sci. 2017 Dec 27;19(1). pii: E68. doi: 10.3390/ijms19010068.
[h=1]Harnessing Invariant NKT Cells to Improve Influenza Vaccines: A Pig Perspective.[/h] Yang G[SUP]1[/SUP], Richt JA[SUP]2,[/SUP][SUP]3[/SUP], Driver JP[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Invariant natural killer T (iNKT) cells are an "innate-like" T cell lineage that recognize glycolipid rather than peptide antigens by their semi-invariant T cell receptors. Because iNKT cells can stimulate an extensive array of immune responses, there is considerable interest in targeting these cells to enhance human vaccines against a wide range of microbial pathogens. However, long overlooked is the potential to harness iNKT cell antigens as vaccine adjuvants for domestic animal species that express the iNKT cell-CD1d system. In this review, we discuss the prospect of targeting porcine iNKT cells as a strategy to enhance the efficiency of swine influenza vaccines. In addition, we compare the phenotype and tissue distribution of porcine iNKT cells. Finally, we discuss the challenges that must be overcome before iNKT cell agonists can be contemplated for veterinary use in livestock.


[h=4]KEYWORDS:[/h] CD1d; adjuvants; iNKT cells; influenza vaccine; pig

PMID: 29280974 DOI: 10.3390/ijms19010068
 
Back
Top Bottom